drugset / Trial / NCT00212108
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Phase 1/2
Completed
22 enrolled
National University Hospital, Singapore
National Healthcare Group, Singapore · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action between COX-2 and EGFR inhibitors. Study hypothesis: Celecoxib and gefitinib can reduce angiogenesis and induce anti-tumorigenicity in patients with nasopharngeal cancer.
Timeline
- Start
- 2003-11
- Primary completion
- 2007-03
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 400 mg | — |
| Subject | Gefitinib | Small molecule | 250 mg | — |